Literature DB >> 15718270

Functional expression of beta-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts.

Shozo Yano1, Romuald Mentaverri, Deepthi Kanuparthi, Sanghamitra Bandyopadhyay, Alicia Rivera, Edward M Brown, Naibedya Chattopadhyay.   

Abstract

The expression and functions of receptors for the beta-chemokine, regulated upon activation, normal T cell expressed, and secreted (RANTES)/CCL5, were investigated in osteoblasts. Both primary osteoblasts and the MC3T3-E1 osteoblast cell line express the RANTES receptors, CCR1, 3, 4, and 5 (by RT-PCR), which encode functional receptors in osteoblasts as shown by [125I]-RANTES binding followed by Scatchard analysis. Expression of all four RANTES receptor mRNAs in osteoblast is in contrast to the reports of expression of CCR1 being the only RANTES receptor expressed by osteoclasts. Exogenous RANTES elicits chemotaxis of osteoblasts and promotes cell survival via phosphatidylinositol 3-kinase with attendant phosphorylation of Akt. Osteoclastic RANTES, obtained from the conditioned medium of receptor activator of nuclear factor-kappa B ligand-differentiated RAW264.7 cells also induces chemotaxis of MC3T3-E1 cells. Incubating the conditioned medium with an anti-RANTES neutralizing antibody attenuated this effect. RANTES secretion from osteoblast is inhibited by differentiation promoting hormones, e.g. 1,25 (OH)2D3 and dexamethasone, whereas macrophage inflammatory protein-1 alpha (but not macrophage inflammatory protein-1 beta) and elevated calcium induce it. Elevated calcium also stimulated RANTES secretion by osteoclasts. Therefore, RANTES is an osteoblast chemoattractant and a survival-promoting molecule whose regulation in osteoblast is varied. Furthermore, RANTES secreted from osteoclasts induces osteoblast chemotaxis. Therefore, expression of RANTES and its receptors in both osteoblasts and osteoclasts could enable this chemokine to act in autocrine/paracrine modes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718270     DOI: 10.1210/en.2005-0065

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  34 in total

1.  Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.

Authors:  Benjamin J Frisch; John M Ashton; Lianping Xing; Michael W Becker; Craig T Jordan; Laura M Calvi
Journal:  Blood       Date:  2011-09-28       Impact factor: 22.113

2.  Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing.

Authors:  Aysegul V Ergen; Nathan C Boles; Margaret A Goodell
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

Review 3.  Osteoblast migration in vertebrate bone.

Authors:  Antonia Thiel; Marie K Reumann; Adele Boskey; Johannes Wischmann; Rüdiger von Eisenhart-Rothe; Philipp Mayer-Kuckuk
Journal:  Biol Rev Camb Philos Soc       Date:  2017-06-19

Review 4.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

5.  TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells.

Authors:  Graeme E Glass; James K Chan; Andrew Freidin; Marc Feldmann; Nicole J Horwood; Jagdeep Nanchahal
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-05       Impact factor: 11.205

6.  CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

Authors:  Daniel J Dairaghi; Babatunde O Oyajobi; Anjana Gupta; Brandon McCluskey; Shichang Miao; Jay P Powers; Lisa C Seitz; Yu Wang; Yibin Zeng; Penglie Zhang; Thomas J Schall; Juan C Jaen
Journal:  Blood       Date:  2012-05-22       Impact factor: 22.113

7.  CCL7 is a protective factor secreted by mechanically loaded osteocytes.

Authors:  Y Kitase; S Lee; J Gluhak-Heinrich; M L Johnson; S E Harris; L F Bonewald
Journal:  J Dent Res       Date:  2014-10-01       Impact factor: 6.116

8.  Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

Authors:  Babafemi O Taiwo; Ellen S Chan; Carl J Fichtenbaum; Heather Ribaudo; Athe Tsibris; Karin L Klingman; Joseph J Eron; Baiba Berzins; Kevin Robertson; Alan Landay; Igho Ofotokun; Todd Brown
Journal:  Clin Infect Dis       Date:  2015-06-09       Impact factor: 9.079

9.  Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis.

Authors:  M Ikić Matijašević; D Flegar; N Kovačić; V Katavić; T Kelava; A Šućur; S Ivčević; H Cvija; E Lazić Mosler; I Kalajzić; A Marušić; D Grčević
Journal:  Clin Exp Immunol       Date:  2016-10-18       Impact factor: 4.330

10.  Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease.

Authors:  Louisa C Johnston; Xiaomin Su; Kathleen Maguire-Zeiss; Karen Horovitz; Irina Ankoudinova; Dmitry Guschin; Piotr Hadaczek; Howard J Federoff; Krystof Bankiewicz; John Forsayeth
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.